About £3.7 million ($4.9 million) of proceeds from the placement would go toward the acquisition, while remaining funds will support assay development validation, and working capital.
The blood-based test is based on three serum biomarkers —matrix metallopeptidase-9, neuron-specific enolase, and vascular cellular adhesion molecule-1.
The firms will collaborate on creating and co-marketing array technologies for research and clinical diagnostics.
The partners will work together to develop serological assays measuring antibodies to determine patient immunity to diseases for which vaccines exist.
Axela and Hutman Diagnostics last week announced progress in the co-development of a multiplex pathogen detection system.
Axela and Hutman Diagnostics have announced an agreement that will deliver a microarray-based, sample-to-answer pathogen detection platform to market next year.
NEW YORK (GenomeWeb News) – Axela today announced a development deal to integrate Thermal Gradient's rapid PCR technology into Axela's Flow-Thru Chip automated workflow.
NEW YORK (GenomeWeb News) – Multiplex instrument developer Axela today announced the hiring of investment bank AmeriTech Advisors to explore strategic opportunities for the firm.
Axela and OvaGene Oncology this week announced a partnership that will see OvaGene's gene signatures related to ovarian cancer treatment become available on Axela's Ziplex array platform.
NEW YORK (GenomeWeb News) – Mount Sinai Services in Toronto and Brigham and Women's Hospital in Boston are collaborating to test Axela's Risk of Recurrence Assay, the company said today.
A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.
Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.
In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.
Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.